If you saw the headline and are wondering whether this policy will end gray-market peptides, here is the short answer. HHS has issued a draft enforcement policy saying it does not intend to act against state-licensed 503A compounding pharmacies that make six named peptides while FDA develops its list of approved bulk ingredients. The policy is aimed at compounding pharmacies, so research-use-only sellers stay outside it. Whether people actually switch is still an open question, and NBC News’s headline asks it directly. Put simply, this is a draft policy HHS may revisit, not an FDA approval.
Disclosure: Some links on this page are affiliate links. We may receive a commission on purchases made through them. There is no extra cost to you.

Quick facts as of 2026-11-14
| Fact | Detail |
|---|---|
| Type of policy | Draft enforcement discretion policy, Federal Register notice published Oct. 30, 2026 |
| Peptides named | BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500 (GPB, Oct. 28, 2026) |
| Who it covers | State-licensed 503A pharmacies, federal facilities and licensed physicians compounding the listed peptides (Federal Register) |
| Not covered | 503B outsourcing facilities (GPB) |
| FDA status | The peptides were not FDA-approved, and the policy does not change their legal status (GPB) |
| Can it change? | Yes. HHS may revisit it if a safety signal or quality problem appears (Federal Register) |
| Availability | Described by GPB as still pending |
What did HHS actually announce?
The main document is the Federal Register notice HHS published on October 30, 2026. It is titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (FR Doc. 2026-22192, docket HHS-OASH-2026-0496), and Health Secretary Robert F. Kennedy Jr. signed it.
The notice says HHS does not intend to act against the groups it names while FDA develops the 503A bulks list. It also says the policy creates no rights. Comments were open for two weeks after publication.
Which six peptides does the policy name?
GPB’s October 28, 2026 report, by Sydney Lupkin, lists these six:
- BPC-157
- Epitalon
- KPV
- MOTS-c
- Semax
- TB-500
GPB says HHS will use “enforcement discretion” so that small 503A compounding pharmacies can make these six without enforcement.
Does the FDA regulate compounding pharmacies?
In one specific way, yes. FDA’s bulk substances page, current as of 05/14/2026, sets the rules for the ingredients compounders can use. A bulk substance must meet a USP/NF monograph, be a component of an FDA-approved drug, or be on the 503A bulks list. Each one needs a certificate of analysis and has to come from an FDA-registered maker.
The Federal Register notice describes the pharmacies in this policy as state-licensed. For a plain explanation of what a certificate of analysis should show, see peptide coa explained.
Are peptides FDA cleared?
No. GPB reports that these six peptides were not FDA-approved, and that the policy does not change their legal status. The policy lets certain pharmacies make them without enforcement. It does not put them through FDA approval.
Who does the policy affect?
According to the Federal Register notice, the policy covers state-licensed pharmacies, federal facilities and licensed physicians who compound the listed peptides. GPB says 503B outsourcing facilities are not covered, and it describes availability as still pending.
GPB quotes people on both sides. Scott Brunner of the Alliance for Pharmacy Compounding says compounding is a more accountable alternative, though verification could delay dispensing. Joshua Fritzler of Olympia and Wesley Pharmaceuticals, a small facility, says it cannot meet demand.
Will this end gray-market peptides?
Nobody can answer that yet. NBC News’s report, by Berkeley Lovelace Jr. on November 13, 2026, asks the question in its headline. Kennedy argues that letting compounding pharmacies make these peptides would keep people from the gray market, according to NBC.
NBC describes Cory Huot, an avid peptide user who orders online and pays for third-party testing, as an example of the people the decision targets. It also says unnamed longtime users say they will not change. That is one person’s account, and it is not a count of how many people use gray-market peptides.
NBC says these peptides are marketed for muscle building, healing and anti-aging, with scant research behind most of those claims. GPB describes the evidence for safety and effectiveness as sparse. For more on the claims people hear, see peptide myths and facts.
Critics are also vocal. Robert Steinbrook of Public Citizen says the policy undermines FDA and skips the usual rulemaking, according to GPB. The Partnership for Safe Medicines has filed a citizen petition asking FDA to disregard the July advisory vote.
What does the policy leave untouched?
Research-use-only sellers stay outside it. GPB reports that the policy frames compounding as safer than “research-use-only” products from questionable overseas suppliers, and that unproven peptides are sold despite an official ban.
A competitor’s explainer on thepeptidesupply.com says research vendors work in a different regulatory space from compounding pharmacies. It says these vendors label products “for research purposes only, not for human use.” That is the explainer’s own description of the market, not a report from HHS or FDA.
What’s the difference between research peptides and regular peptides?
The main difference is who makes and sells them, and how they are overseen. The table below sets out the two side by side.
| Feature | Research-use-only | 503A compounded |
|---|---|---|
| Who sells it | Research vendors, per thepeptidesupply.com’s explainer | State-licensed 503A pharmacies, with licensed physicians, per the Federal Register notice |
| Oversight described | “There is no FDA inspection of research chemical labs,” per thepeptidesupply.com’s explainer | FDA bulk substance rules apply, including a certificate of analysis for each substance (FDA) |
| Covered by the HHS draft policy | Outside it | Enforcement discretion for the six named peptides while FDA develops the bulks list (Federal Register) |
Key dates
| Date | What happened | Source |
|---|---|---|
| Oct. 28, 2026 | GPB reports HHS will allow pharmacies to make six popular peptides | GPB |
| Oct. 30, 2026 | The Federal Register notice is published (FR Doc. 2026-22192) | Federal Register |
| Two weeks after publication | Comment period on the notice closes | Federal Register |
| Nov. 13, 2026 | NBC News and ArentFox Schiff publish on the policy | NBC News; JD Supra |
Common mix-ups
| Mix-up | What’s true |
|---|---|
| “503A and 503B are the same thing.” | GPB says 503B outsourcing facilities are not covered by the policy. |
| “Research peptides and compounded peptides are the same.” | They have different sellers and different oversight. See the table above. |
| “The policy is permanent.” | ArentFox Schiff’s JD Supra note says it is revocable, and HHS may revisit it. |
Questions to settle your next step
Before you decide anything, these are the questions that matter most. Take them to your prescriber or a pharmacist.
- Is the pharmacy a state-licensed 503A pharmacy?
- Where was each ingredient made? ArentFox Schiff’s JD Supra note advises compounders to verify the original manufacturer of Chinese-sourced ingredients.
- Does each ingredient come with a certificate of analysis from an FDA-registered maker?
- For a checklist of what to look for in any peptide company, see how to verify a peptide company.
On safety, the reporting is thin. NBC says most marketed claims have scant research behind them, and GPB calls the safety and effectiveness evidence sparse. If you are already using one of these peptides, the person who prescribed it or a pharmacist is the right person to talk through what this policy means for your supply.
By The Nerve & Joint Pain Desk Editorial Team
Keep reading